Home » Stocks » AXSM

Axsome Therapeutics, Inc. (AXSM)

Stock Price: $75.18 USD 1.76 (2.40%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $75.54 +0.36 (0.48%) Nov 27, 3:17 PM

Stock Price Chart

Key Info

Market Cap 2.81B
Revenue (ttm) n/a
Net Income (ttm) -98.54M
Shares Out 37.34M
EPS (ttm) -2.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $75.18
Previous Close $73.42
Change ($) 1.76
Change (%) 2.40%
Day's Open 73.35
Day's Range 73.13 - 75.33
Day's Volume 127,183
52-Week Range 35.44 - 109.94

More Stats

Market Cap 2.81B
Enterprise Value 2.65B
Earnings Date (est) Mar 18, 2021
Ex-Dividend Date n/a
Shares Outstanding 37.34M
Float 29.36M
EPS (basic) -2.70
EPS (diluted) -2.70
FCF / Share -2.02
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.45M
Short Ratio 11.99
Short % of Float 11.74%
Beta 2.83
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 20.27
Revenue n/a
Operating Income -95.83M
Net Income -98.54M
Free Cash Flow -75.50M
Net Cash 154.33M
Net Cash / Share 4.13
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -48.29%
ROE -138.71%
ROIC -2,274.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (11)

Buy 10
Overweight 0
Hold 0
Underweight 1
Sell 0

Analyst Consensus: Buy

Price Target

(95.41% upside)
Current: $75.18
Target: 146.91
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-67.25-32.85-27.16-27.54-9.20-5.67-1.84
Net Income-68.35-30.97-28.94-27.20-12.21-6.00-2.17
Shares Outstanding34.0226.8822.7619.1511.959.107.69
Earnings Per Share-2.01-1.15-1.27-1.42-1.02-0.66-0.28
Operating Cash Flow-46.38-30.05-26.47-21.28-7.44-4.60-1.63
Capital Expenditures-0.02-0.03-0.01-0.10-0.02--
Free Cash Flow-46.39-30.09-26.48-21.39-7.46-4.60-1.63
Cash & Equivalents22013.9734.0236.6248.042.622.09
Total Debt19.936.919.939.74-4.483.83
Net Cash / Debt2007.0624.0926.8848.04-1.87-1.74
Book Value1790.9416.7221.5746.44-3.20-2.03
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Axsome Therapeutics, Inc.
Country United States
Employees 53
CEO Herriott Tabuteau

Stock Information

Ticker Symbol AXSM
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AXSM
IPO Date November 19, 2015


Axsome Therapeutics, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the phase III clinical trial for the treatment resistant depression and depressive disorders; and phase II/III clinical trials in agitation associated with Alzheimer's disease, as well as completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07, which is in phase III clinical trial for the treatment of migraine; AXS-09 that has completed phase II clinical trial for the treatment of various CNS disorders; AXS-12, which has completed phase II clinical trial for the treatment of in narcolepsy; and AXS-14, an investigational medicine that is in phase III for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was founded in 2012 and is based in New York, New York.